{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:04:33Z","timestamp":1795061073468,"version":"4.10.2"},"reference-count":36,"publisher":"Oxford University Press (OUP)","issue":"14","license":[{"start":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T00:00:00Z","timestamp":1642032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Akcea Therapeutics"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>A randomized, double-blind, placebo-controlled, dose-ranging study was conducted in 114 patients with fasting serum triglycerides 200\u2013500 mg\/dL (2.26\u20135.65 mmol\/L). Patients received olezarsen (10 or 50 mg every 4 weeks, 15 mg every 2 weeks, or 10 mg every week) or saline placebo subcutaneously for 6\u201312 months. The primary endpoint was the percent change in fasting triglyceride levels from baseline to Month 6 of exposure. Baseline median (interquartile range) fasting triglyceride levels were 262 (222\u2013329) mg\/dL [2.96 (2.51\u20133.71) mmol\/L]. Treatment with olezarsen resulted in mean percent triglyceride reductions of 23% with 10 mg every 4 weeks, 56% with 15 mg every 2 weeks, 60% with 10 mg every week, and 60% with 50 mg every 4 weeks, compared with increase by 6% for the pooled placebo group (P-values ranged from 0.0042 to &amp;lt;0.0001 compared with placebo). Significant decreases in apoC-III, very low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B were also observed. There were no platelet count, liver, or renal function changes in any of the olezarsen groups. The most common adverse event was mild erythema at the injection site.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Olezarsen significantly reduced apoC-III, triglycerides, and atherogenic lipoproteins in patients with moderate hypertriglyceridaemia and at high risk for or with established cardiovascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>NCT03385239.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehab820","type":"journal-article","created":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T15:11:50Z","timestamp":1637939510000},"page":"1401-1412","source":"Crossref","is-referenced-by-count":211,"title":["Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk"],"prefix":"10.1093","volume":"43","author":[{"given":"Jean-Claude","family":"Tardif","sequence":"first","affiliation":[{"name":"Jean-Claude Tardif MD Research Center, Montreal Heart Institute , 5000 Belanger Street, Montreal, PQ H1T1C8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6371-5834","authenticated-orcid":false,"given":"Ewa","family":"Karwatowska-Prokopczuk","sequence":"additional","affiliation":[{"name":"Akcea Therapeutics , 55 Cambridge Parkway Suite 100 Cambridge, Boston, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric St","family":"Amour","sequence":"additional","affiliation":[{"name":"Eric St-Amour, MD 214 Cite des jeunes Gatineau , QC J8Y 6S8, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M","family":"Ballantyne","sequence":"additional","affiliation":[{"name":"Department of Medicine, Baylor College of Medicine , One Baylor Plaza, MS BCM285, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-3287","authenticated-orcid":false,"given":"Michael D","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Wake Forest University School of Medicine, Section on Cardiovascular Medicine 1, Medical Center Boulevard , Winston-Salem, NC 27157, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M","family":"Moriarty","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Internal Medicine, University of Kansas Medical Center , 3901 Rainbow Blvd., Kansas City, KS 66160, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1202-8126","authenticated-orcid":false,"given":"Seth J","family":"Baum","sequence":"additional","affiliation":[{"name":"Clinical Affiliate Professor of Cardiology, Department of Integrated Medical Science, Charles E. Schmidt College of Medicine, Florida Atlantic University, 777 Glades Road, BC-71 Boca Raton, FL 33431, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8189-5093","authenticated-orcid":false,"given":"Eunju","family":"Hurh","sequence":"additional","affiliation":[{"name":"Akcea Therapeutics , 55 Cambridge Parkway Suite 100 Cambridge, Boston, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1080-3822","authenticated-orcid":false,"given":"Victoria J","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Akcea Therapeutics , 55 Cambridge Parkway Suite 100 Cambridge, Boston, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce","family":"Kingsbury","sequence":"additional","affiliation":[{"name":"Akcea Therapeutics , 55 Cambridge Parkway Suite 100 Cambridge, Boston, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo L","family":"Figueroa","sequence":"additional","affiliation":[{"name":"Akcea Therapeutics , 55 Cambridge Parkway Suite 100 Cambridge, Boston, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3729-5749","authenticated-orcid":false,"given":"Veronica J","family":"Alexander","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA 92010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Tami","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA 92010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph L","family":"Witztum","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism, University of California, San Diego , 9500 Gilman Drive, BSB1080 La Jolla, CA 92093-0682, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S","family":"Geary","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA 92010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis St L","family":"O\u2019Dea","sequence":"additional","affiliation":[{"name":"Akcea Therapeutics , 55 Cambridge Parkway Suite 100 Cambridge, Boston, MA 02142, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-9494","authenticated-orcid":false,"given":"Sotirios","family":"Tsimikas","sequence":"additional","affiliation":[{"name":"Ionis Pharmaceuticals, Inc. , 2855 Gazelle Court, Carlsbad, CA 92010, USA"},{"name":"Division of Cardiovascular Medicine, University of California, San Diego , 9500 Gilman Drive, BSB1080 La Jolla, CA 92093-0682, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"Department of Medicine, Universit\u00e9 de Montr\u00e9al and Ecogene-21 Clinical Research Centre , Chicoutimi, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,13]]},"reference":[{"key":"2022102517002567300_ehab820-B1","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"2022102517002567300_ehab820-B2","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/j.jacc.2015.03.544","article-title":"Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins","volume":"65","author":"Schwartz","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102517002567300_ehab820-B3","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1210\/jc.2018-00470","article-title":"Increased cardiovascular risk in hypertriglyceridemic patients with statin-controlled LDL cholesterol","volume":"103","author":"Nichols","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2022102517002567300_ehab820-B4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/eurheartj\/ehz785","article-title":"Clinical review on triglycerides","volume":"41","author":"Laufs","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102517002567300_ehab820-B5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102517002567300_ehab820-B6","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"2022102517002567300_ehab820-B7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.atherosclerosis.2019.12.005","article-title":"Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM","volume":"294","author":"Nordestgaard","year":"2020","journal-title":"Atherosclerosis"},{"key":"2022102517002567300_ehab820-B8","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1161\/CIRCULATIONAHA.117.032318","article-title":"Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial","volume":"138","author":"Vallejo-Vaz","year":"2018","journal-title":"Circulation"},{"key":"2022102517002567300_ehab820-B9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.tips.2015.07.001","article-title":"Apolipoprotein C-III: from pathophysiology to pharmacology","volume":"36","author":"Norata","year":"2015","journal-title":"Trends Pharmacol Sci"},{"key":"2022102517002567300_ehab820-B10","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1056\/NEJMoa1400284","article-title":"Targeting APOC3 in the familial chylomicronemia syndrome","volume":"371","author":"Gaudet","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102517002567300_ehab820-B11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11883-019-0791-9","article-title":"Emerging evidence that apoC-III inhibitors provide novel options to reduce the residual CVD","volume":"21","author":"Taskinen","year":"2019","journal-title":"Curr Atheroscler Rep"},{"key":"2022102517002567300_ehab820-B12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"Jorgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102517002567300_ehab820-B13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1307095","article-title":"Loss-of-function mutations in APOC3, triglycerides, and coronary disease","volume":"371","author":"Crosby","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102517002567300_ehab820-B14","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/ATVBAHA.117.310473","article-title":"APOC3 Loss-of-function mutations, remnant cholesterol, low-density lipoprotein cholesterol, and cardiovascular risk: mediation- and meta-analyses of 137 895 individuals","volume":"38","author":"Wulff","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102517002567300_ehab820-B15","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jacl.2015.05.002","article-title":"The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis","volume":"9","author":"Wyler von Ballmoos","year":"2015","journal-title":"J Clin Lipidol"},{"key":"2022102517002567300_ehab820-B16","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/ATVBAHA.117.309007","article-title":"Apolipoprotein C-III levels and incident coronary artery disease risk: the EPIC-Norfolk prospective population study","volume":"37","author":"van Capelleveen","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102517002567300_ehab820-B17","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1373\/clinchem.2008.103234","article-title":"Increased plasma apolipoprotein C-III concentration independently predicts cardiovascular mortality: the Hoorn Study","volume":"54","author":"Scheffer","year":"2008","journal-title":"Clin Chem"},{"key":"2022102517002567300_ehab820-B18","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1093\/eurheartj\/ehz209","article-title":"N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels","volume":"40","author":"Alexander","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102517002567300_ehab820-B19","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense inhibition of apolipoprotein C-III in patients with hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N Engl J Med"},{"key":"2022102517002567300_ehab820-B20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","article-title":"Volanesorsen and triglyceride levels in familial chylomicronemia syndrome","volume":"381","author":"Witztum","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102517002567300_ehab820-B21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","article-title":"Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Gouni-Berthold","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102517002567300_ehab820-B22","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/joim.13059","article-title":"Contribution of remnant cholesterol to cardiovascular risk","volume":"288","author":"Langsted","year":"2020","journal-title":"J Intern Med"},{"key":"2022102517002567300_ehab820-B23","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1016\/j.jacc.2020.10.008","article-title":"Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease","volume":"76","author":"Casta\u00f1er","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102517002567300_ehab820-B24","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1016\/j.jacc.2020.09.610","article-title":"VLDL cholesterol accounts for one-half of the risk of myocardial infarction associated with apoB-containing lipoproteins","volume":"76","author":"Balling","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102517002567300_ehab820-B25","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes: a systematic review and meta-regression analysis of randomized controlled trials","volume":"140","author":"Marston","year":"2019","journal-title":"Circulation"},{"key":"2022102517002567300_ehab820-B26","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cmet.2014.08.007","article-title":"APOC3, coronary disease, and complexities of Mendelian randomization","volume":"20","author":"Cohen","year":"2014","journal-title":"Cell Metab"},{"key":"2022102517002567300_ehab820-B27","doi-asserted-by":"crossref","first-page":"100010","DOI":"10.1194\/jlr.ILR120001217","article-title":"Apolipoprotein C3 and apolipoprotein B colocalize in proximity to macrophages in atherosclerotic lesions in diabetes","volume":"62","author":"Kanter","year":"2020","journal-title":"J Lipid Res"},{"key":"2022102517002567300_ehab820-B28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41590-019-0548-1","article-title":"Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation","volume":"21","author":"Zewinger","year":"2020","journal-title":"Nat Immunol"},{"key":"2022102517002567300_ehab820-B29","doi-asserted-by":"crossref","first-page":"3936","DOI":"10.1093\/eurheartj\/ehaa689","article-title":"Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia","volume":"41","author":"Gaudet","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102517002567300_ehab820-B30","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","article-title":"Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides","volume":"377","author":"Graham","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102517002567300_ehab820-B31","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2022102517002567300_ehab820-B32","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1172\/JCI86610","article-title":"ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors","volume":"126","author":"Gordts","year":"2016","journal-title":"J Clin Invest"},{"key":"2022102517002567300_ehab820-B33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.jacl.2017.04.043","article-title":"Natural history (up to 15 years) of platelet count in 84 patients with familial hyperchylomicronemia due to lipoprotein lipase deficiency","volume":"11","author":"Gaudet","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2022102517002567300_ehab820-B34","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.amjcard.2010.11.008","article-title":"Prevalence of severe (500 to 2,000 mg\/dl) hypertriglyceridemia in United States adults","volume":"107","author":"Christian","year":"2011","journal-title":"Am J Cardiol"},{"key":"2022102517002567300_ehab820-B35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1089\/nat.2018.0753","article-title":"Integrated assessment of the clinical performance of GalNAc3-conjugated 2\u2032-O-methoxyethyl chimeric antisense oligonucleotides: I. Human volunteer experience","volume":"29","author":"Crooke","year":"2019","journal-title":"Nucleic Acid Ther"},{"key":"2022102517002567300_ehab820-B36","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"AKCEA-APO(a)-LRx Study Investigators. Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/14\/1401\/46629468\/ehab820.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/43\/14\/1401\/46629468\/ehab820.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T14:16:24Z","timestamp":1666707384000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/43\/14\/1401\/6506552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,13]]},"references-count":36,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,1,13]]},"published-print":{"date-parts":[[2022,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehab820","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,4,7]]},"published":{"date-parts":[[2022,1,13]]}}}